表紙
市場調査レポート

末梢動脈疾患 (PAD) /末梢血管疾患 (PVD):パイプライン製品の分析

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 264085
出版日 ページ情報 英文 180 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.51円で換算しております。
Back to Top
末梢動脈疾患 (PAD) /末梢血管疾患 (PVD):パイプライン製品の分析 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H1 2016
出版日: 2016年05月18日 ページ情報: 英文 180 Pages
概要

末梢血管疾患 (PVD) は、心臓と脳の外側にある血管 (動脈・静脈) の疾患を指します。腰・もも・ふくらはぎの痛みを伴う痙攣 (間欠性跛行) 、脚のしびれ・脱力、下腿・足先の冷たさ、足の指の痛み、治癒しない足・脚、成長が遅い足の爪、男性の勃起障害などの症状が見られます。

当レポートでは、末梢動脈疾患 (PAD) /末梢血管疾患 (PVD) に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

末梢動脈疾患 (PAD)/末梢血管疾患 (PVD)の概要

治療薬の開発

  • パイプライン製品の概要

末梢動脈疾患 (PAD)/末梢血管疾患 (PVD):企業で開発中の治療薬

末梢動脈疾患 (PAD)/末梢血管疾患 (PVD):パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

末梢動脈疾患 (PAD)/末梢血管疾患 (PVD):企業で開発中の製品

末梢動脈疾患 (PAD)/末梢血管疾患 (PVD)の治療薬開発に従事している企業

  • Alvogen Korea Co., Ltd.
  • AnGes MG, Inc.
  • AstraZeneca Plc
  • Athersys, Inc.
  • Bayer AG
  • Betagenon AB
  • CardioVascular BioTherapeutics, Inc.
  • Celgene Corporation
  • Hemostemix Ltd
  • ID Pharma Co., Ltd.
  • Juventas Therapeutics, Inc.
  • miRagen Therapeutics, Inc.
  • Multi Gene Vascular Systems Ltd
  • Nuo Therapeutics, Inc.
  • Proteon Therapeutics, Inc.
  • Recardio GmbH
  • Resverlogix Corp.
  • Sigma-Tau S.p.A.
  • Stemedica Cell Technologies, Inc.
  • Symic Biomedical, Inc.
  • Theravasc, Inc.
  • ViroMed Co., Ltd.
  • Yuyu Pharma, Inc.

末梢動脈疾患 (PAD)/末梢血管疾患 (PVD):治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

末梢動脈疾患 (PAD)/末梢血管疾患 (PVD):最近のパイプライン動向

末梢動脈疾患 (PAD)/末梢血管疾患 (PVD):休止中のプロジェクト

末梢動脈疾患 (PAD)/末梢血管疾患 (PVD):開発が中止された製品

末梢動脈疾患 (PAD)/末梢血管疾患 (PVD):製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8029IDB

Summary

Global Markets Direct's, 'Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H1 2016', provides an overview of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)
  • The report reviews pipeline therapeutics for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) therapeutics and enlists all their major and minor projects
  • The report assesses Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Overview
    • Therapeutics Development
  • Pipeline Products for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Overview
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics under Development by Companies
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Products under Development by Companies
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Companies Involved in Therapeutics Development
    • Alvogen Korea Co., Ltd.
    • AnGes MG, Inc.
    • AstraZeneca Plc
    • Athersys, Inc.
    • Bayer AG
    • Betagenon AB
    • CardioVascular BioTherapeutics, Inc.
    • Celgene Corporation
    • Hemostemix Ltd
    • ID Pharma Co., Ltd.
    • Juventas Therapeutics, Inc.
    • miRagen Therapeutics, Inc.
    • Multi Gene Vascular Systems Ltd
    • Nuo Therapeutics, Inc.
    • Proteon Therapeutics, Inc.
    • Recardio GmbH
    • Resverlogix Corp.
    • Sigma-Tau S.p.A.
    • Stemedica Cell Technologies, Inc.
    • Symic Biomedical, Inc.
    • Theravasc, Inc.
    • ViroMed Co., Ltd.
    • Yuyu Pharma, Inc.
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ACP-01 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AEM-28 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALD-301 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Annexin A-5 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • apabetalone - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • beperminogene perplasmid - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CVBT-141C - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DVC-10101 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ELS-140 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • JVS-100 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • levocarnitine propionate hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MGN-6114 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MultiGeneAngio - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • O-304 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PDA-002 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PF-05285401 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • REC-03 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Rejuveinix - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rivaroxaban - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • sarpogrelate SR - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SB-030 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • sodium nitrite SR - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Stem Cell Therapy for Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease, Infectious Disease and Toxicology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ticagrelor - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TXA-127 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • V-10 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VM-202 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • vonapanitase - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • YY-984 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Recent Pipeline Updates
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Discontinued Products
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Product Development Milestones
    • Featured News & Press Releases
      • Apr 13, 2016: Proteon Therapeutics Announces Publication in the Journal of Cardiovascular Pharmacology of Promising Nonclinical Results for Vonapanitase in Peripheral Artery Disease
      • Feb 04, 2016: Juventas Therapeutics Enrolls First Patient in Phase 2 Gene Therapy Clinical Trial for Treatment of Advanced Peripheral Artery Disease
      • Oct 12, 2015: Proteon Therapeutics Announces Results from Phase 1 Study of Investigational Drug Vonapanitase in Patients with Symptomatic Peripheral Artery Disease Presented at TCT 2015
      • Aug 13, 2015: Proteon Therapeutics Announces Top-Line Results From Phase 1 Study of Investigational Drug Vonapanitase in Patients With Symptomatic Peripheral Artery Disease
      • Feb 02, 2015: The Small molecule AMPK activator O304 acts as an oral PCSK9 inhibitor
      • Jan 08, 2015: Journal of Cardiovascular Pharmacology Publishes Positive Nonclinical Results of Proteon Therapeutics' PRT-201 in Peripheral Artery Disease
      • Sep 02, 2014: Capstone Therapeutics Announces Phase 1a Results for AEM-28 Showing Safety and Biomarker Efficacy Signals
      • Mar 17, 2014: AstraZeneca Announces Progress on Global PARTHENON Clinical Trial Program with BRILINTA in High-Risk Cardiovascular Disease Patient Populations in Advance of American College of Cardiology Scientific Session
      • Mar 05, 2013: Tarix Pharma's Peptide Technology Stimulates Revascularization Following Ischemia
      • Dec 06, 2012: Cytomedix Announces Landmark Bright Cell Therapy Study In Peripheral Arterial Disease
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Alvogen Korea Co., Ltd., H1 2016
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by AnGes MG, Inc., H1 2016
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by AstraZeneca Plc, H1 2016
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Athersys, Inc., H1 2016
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Bayer AG, H1 2016
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Betagenon AB, H1 2016
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by CardioVascular BioTherapeutics, Inc., H1 2016
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Celgene Corporation, H1 2016
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Hemostemix Ltd, H1 2016
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by ID Pharma Co., Ltd., H1 2016
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Juventas Therapeutics, Inc., H1 2016
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by miRagen Therapeutics, Inc., H1 2016
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Multi Gene Vascular Systems Ltd, H1 2016
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Nuo Therapeutics, Inc., H1 2016
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Proteon Therapeutics, Inc., H1 2016
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Recardio GmbH, H1 2016
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Resverlogix Corp., H1 2016
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Sigma-Tau S.p.A., H1 2016
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Stemedica Cell Technologies, Inc., H1 2016
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Symic Biomedical, Inc., H1 2016
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Theravasc, Inc., H1 2016
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by ViroMed Co., Ltd., H1 2016
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Yuyu Pharma, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics - Recent Pipeline Updates, H1 2016
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects, H1 2016
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects (Contd..1), H1 2016
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects (Contd..2), H1 2016
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects (Contd..3), H1 2016
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top